CCL2 and metabolic syndrome: Given the present result, an anti-MCP1 strategy or a better understanding of the mechanism of immunotherapeutic agents may have potential therapeutic value to reduce the detrimental interrelationship between FGF23, dyslipidemia, and inflammation based on CV pathophysiological mechanisms in CKD.